ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Liver Retransplantation (reLT) in the Modern Post-MELD, Post-DAA Era

B. Shi, C. Freise, D. Brandman

School of Medicine, UCSF, San Francisco, CA

Meeting: 2020 American Transplant Congress

Abstract number: 374

Keywords: Retransplantation

Session Information

Session Name: Liver Retransplantation and Other Complications

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:15pm-4:27pm

Location: Virtual

*Purpose: Liver retransplantation (reLT) is responsible for a small proportion of all liver transplants (LT), but outcomes are much worse than primary LT. Hepatitis C recurrence as the indication for reLT has decreased with the advent of direct acting antivirals (DAA). The purpose of this study is to characterize reLT in the modern era, and identify differences in outcomes after reLT over time, across different eras.

*Methods: We retrospectively analyzed data from UNOS for adults undergoing first reLT from 2/27/02-12/31/17. Patients were compared across three eras: 1 (2002-6), 2 (2007-11), and 3 (2012-17) and according to HCV status. Primary outcome is patient survival.

*Results: Of 5483 reLT identified, 1991 occurred in era 1, 1819 in era 2 and 1680 in era 3. Median age was 52, 34% were women, and 34% had HCV as indication for primary LT. Median time from 1st LT to reLT was 355 days. Differences between the three eras included older patients at reLT (era 3 median age=53) and increased median time to reLT (era 3 median=594 days). ReLT indications were most commonly vascular complications and HCV. Third most common reLT indication was rejection in eras 1 and 2, and non-hepatitis recurrent disease in era 3. Recurrent HCV in original graft also decreased from 19% in era 1 and 20% in era 2 to 14% in era 3 (p<0.01). MELD exception status became more common from era 1 to 3 (12 vs 17 vs 28%; p<0.01) and calculated MELD-Na at reLT was higher (27 vs 28 vs 30; p<0.01). Donor quality was better in more recent eras (donor risk index (DRI) 1.4 vs 1.3 vs 1.3; p=0.03). Post reLT survival improved across eras at 1, 3, and 5-years: 73, 64, and 58% in era 1; 78, 71, and 66% in era 2; and 83, 75, and 68% for era 3 (logrank, p<0.01). Patients with recurrent HCV at reLT had worse survival at 1, 3, and 5 years (74, 65, 58%) compared to those who did not (78, 71, 65%) (logrank, p<0.01). In multivariate cox regression, age, recurrent HCV, MELD-Na at reLT, illness severity (i.e. on mechanical ventilation, in the ICU), diabetes mellitus (DM), and DRI were associated with worse post reLT mortality, and era remained a predictor of improved mortality. ICU status and DRI remained significant predictors of mortality, regardless of era or HCV status. MELD exception status was associated with improved post reLT mortality only in era 3.

*Conclusions: Need for reLT has decreased over time, particularly with regard to recurrent HCV, with improved post reLT survival. Factors have been identified (recipient DM and DRI) which could be important in determining optimal candidates for reLT, in light of the growing population with DM and NAFLD.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Shi B, Freise C, Brandman D. Liver Retransplantation (reLT) in the Modern Post-MELD, Post-DAA Era [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/liver-retransplantation-relt-in-the-modern-post-meld-post-daa-era/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences